BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-951@pharmaconomics
DTSTAMP:20260707T033828Z
DTSTART;VALUE=DATE:20260515
DTEND;VALUE=DATE:20260516
SUMMARY:INTI Phase 3 — itraconazole
DESCRIPTION:Phase 3 trial results for itraconazole in Basal Cell Carcinoma Nevus Syndrome (BCCNS) are due May 15\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1042418/000149315226014517/ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/951
URL:https://pharmaconomics.com/e/951
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INTI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR